U.S. Full Prescribing Information Medication Guide Indication U.S. Healthcare Professionals |En Español
Call
1-888-SOTYKTU
(768-9588)

Moderate to severe plaque psoriasis may be a big part of your life, but it doesn’t have to define you.

Together with award-winning actor Ted Danson and others navigating this condition, we celebrate the strength of their inner vibe, the "it" factor that makes someone uniquely them. Watch the first episode featuring Ted and others impacted by plaque psoriasis.

HONOR
YOUR “IT”

With Ted & Emily

Ted Danson and SOTYKTU patient Emily discuss living with plaque psoriasis, focusing on personal
stories of resilience and self-advocacy.

Ted Danson interviews SOTYKTU™ patient Emily about living with moderate to severe plaque psoriasis

Ted is not taking SOTYKTU, and Emily is a real patient currently taking
SOTYKTU. Both participants have been compensated for their time.

View Transcript +
“

Psoriasis is an unscripted part of my life’s storyline. It’s not always comfortable, but it’s part of me. Through ‘SO, Have You Found It?’, I’m spotlighting the steps you can take to navigate this condition and celebrating the unique journeys of individuals managing plaque psoriasis.

– Ted Danson

Check back for new episodes

Ted Danson speaking with Emily, a patient living with moderate to severe plaque psoriasis
Ted Danson speaking with Emily, a patient living with moderate to severe plaque psoriasis

A path to self-empowerment

Your experience with plaque psoriasis is as unique as you are. Here are some ways to be a self-advocate:

Have candid conversations with your dermatologist about your condition

For more facts and resources to help inform those conversations, see below or visit sotyktu.com.

Connect with others and find strength in shared experiences through support groups

Explore treatment options, like SOTYKTU, with your dermatologist

Emily, a SOTYKTU™ (deucravacitinib) patient living with moderate to severe plaque psoriasis

Rethinking treatment for your moderate to severe plaque psoriasis?

Everyone’s experience is different, and a conversation with your dermatologist is the first step toward finding out if SOTYKTU, an FDA-approved medicine for adults with moderate to severe plaque psoriasis, is right for you.

Some facts to know when talking to your doctor:

Clear or almost clear skin was seen by half of people taking SOTYKTU

In one study, 50% of people taking SOTYKTU saw clear or almost clear skin vs 9% taking placebo at 16 weeks.

In the same study, skin clearance was also measured in a different way. A majority of people taking SOTYKTU saw 75% clearer skin vs those taking placebo (53% vs 9%).

In two studies of people with moderate to severe plaque psoriasis including 1,684 adults, 841 people received SOTYKTU, 422 received Otezla® (apremilast), and 421 received placebo. Patients were assessed at 16, 24, and 52 weeks.

SOTYKTU is the better pill for clearer skin

Almost twice as many people had 90% clearer skin
with SOTYKTU compared to the leading pill.*

AT 24 WEEKS. In one study, 42% of people taking SOTYKTU saw 90% clearer skin vs 22% taking the leading pill.* In a second study, 32% of people taking SOTYKTU saw 90% clearer skin vs 20% taking the leading pill.*

Please see the most common side effects for SOTYKTU here.

SOTYKTU™ (deucravacitinib) 6mg pill SOTYKTU™ (deucravacitinib) 6mg pill

SOTYKTU is the first of its kind† once-daily pill

It can be taken wherever you are, with or without food and at any time that fits your schedule best.

*Otezla® (apremilast).
†Selective TYK2 inhibitor.

There's only one SOTYKTU, so ask for it by name.

Learn more about SOTYKTU and find resources for
discussing treatment with your dermatologist

GET TO KNOW SOTYKTU BROCHURE

An introduction to SOTYKTU
featuring trial results, safety
information, how it works,
and more.

DOWNLOAD  

DOCTOR DISCUSSION GUIDE

Make your next dermatologist appointment your best one yet with this guide. It’s perfect for jotting down notes before, during, or after a chat with your doctor.

DOWNLOAD  

SKIN CLEARANCE RESULTS

Take a look at the efficacy and
safety results of SOTYKTU.

LEARN MORE  

SAFETY INFORMATION

LEARN MORE  

RESOURCES AND SUPPORT

Whether you’re considering SOTYKTU and want to know what’s available to you or you’ve started on SOTYKTU and are interested in support materials that may help you along your treatment path, look here for downloadable resources and information to help.

LEARN MORE  
Important Facts About
SOTYKTU™
(deucravacitinib)
This is a summary of important information that you need to know about SOTYKTU. Your dermatologist can work with you to help answer any questions you may have about this medication. Keep this information in a safe place, so you can refer to it before and during your treatment.
This is a summary of important information that you need to know about SOTYKTU. Your dermatologist can work with you to help answer any questions you may have about this medication. Keep this information in a safe place, so you can refer to it before and during your treatment.
Look out for the following icons as you read:
Talk to your dermatologist
Call a dermatologist right away
Helpful information to remember
What is SOTYKTU?
SOTYKTU is an oral prescription medication that is used to treat:
Moderate-to-severe plaque psoriasis in adults who may benefit from systemic therapy (pills or injections that work inside the body) or phototherapy (treatment using specialized ultraviolet or UV light).
It is not known if SOTYKTU is safe
and effective in children under 18
years of age.
What is the most important information I should know about SOTYKTU?
SOTYKTU may cause serious side effects, including:
Serious allergic reactions. Stop taking SOTYKTU and get emergency medical help right away if you develop
any of the following symptoms of a serious allergic reaction:
  • Feeling faint
  • Swelling of your face, eyelids,
    lips, mouth, tongue, or throat
  • Trouble breathing or
    throat tightness
  • Chest tightness
  • Skin rash, hives
Infections. SOTYKTU is a medicine that affects your immune system. SOTYKTU can lower the ability of your immune system to fight infections and can increase your risk of infections. Your dermatologist should check you for infections before starting SOTYKTU. Some people have had serious infections while taking SOTYKTU, such as infections of the lungs, including pneumonia and tuberculosis (TB) and COVID-19.
Before starting SOTYKTU, your dermatologist should check you for TB. If you have active TB or a history of TB, you may be treated for TB before beginning treatment with SOTYKTU. Your dermatologist should watch you closely for signs and symptoms of TB during treatment with SOTYKTU.
If you get a serious infection, your dermatologist may tell you to stop taking SOTYKTU until your infection is controlled.
Call or see a dermatologist if you notice any symptoms of TB.
Call or see a dermatologist right away if you have an infection or develop any new or worsening symptoms of an infection, including:
  • Fever, sweats, or chills
  • Muscle aches
  • Weight loss
  • Cough
  • Shortness of breath
  • Blood in your phlegm (mucus you cough up)
  • Warm, red, or painful skin or sores on your body different from your psoriasis
  • Diarrhea or stomach pain
  • Burning when you urinate or urinating more often than normal
  • Feeling very tired
SOTYKTU should not be used in people with an active, serious infection, including localized infections. You should not start taking SOTYKTU if you have any kind of infection unless your dermatologist tells you it is okay.
You may be at higher risk of developing shingles (herpes zoster).
Before starting SOTYKTU, tell your dermatologist if you:
  • Have any kind of infection or symptoms of an infection (see symptoms listed in “What is the most important information I should know about SOTYKTU?”), as SOTYKTU may lower the ability of your immune system to fight infections and may increase your risk of infections. Infections include:
    • Any infection for which you are currently being treated.
    • Any infection that will not go away or a history of infections that keep coming back.
    • Tuberculosis (TB), a type of lung infection. Tell your dermatologist if you have TB or have been in close contact with someone with TB.
    • Hepatitis B or C. Tell your dermatologist if you have or have had hepatitis B or C.
After you start taking SOTYKTU, call your dermatologist right away if you have an infection or symptoms of an infection. SOTYKTU can make you more likely to get infections or make any infections you have worse.
Cancer. Certain kinds of cancer including lymphoma have been reported in people taking SOTYKTU. Tell your dermatologist if you have ever had any type of cancer.
Muscle problems (rhabdomyolysis). SOTYKTU can cause muscle problems that can be severe. Treatment with SOTYKTU may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Increased CPK is common in people taking SOTYKTU. Your dermatologist may tell you to stop taking SOTYKTU if the amount of CPK in your blood gets too high or if you have signs and symptoms of severe muscle problems. Tell your dermatologist right away if you have any of these signs or symptoms of severe muscle problems:
  • Unexplained muscle pain, tenderness, or weakness
  • Feeling very tired
  • Fever
  • Dark-colored urine
A serious side effect is a side effect that may require medical treatment or hospitalization, cause permanent damage, or be life-threatening or sometimes even fatal.
What should I discuss with my dermatologist before starting treatment?
Talk to your dermatologist about all of your medical conditions, including if:
  • You have liver or kidney problems.
  • You have high levels of fat in your blood (triglycerides).
Talk to your dermatologist if you have recently received or are scheduled to receive a vaccine (immunization).
During treatment with SOTYKTU, you should avoid receiving live vaccines (vaccines that use a small
amount of the weakened virus). Common live vaccines (among others) include:
  • Measles, mumps, and rubella (MMR)
  • Rotavirus
  • Smallpox
  • Chickenpox
  • Yellow fever
Talk to your dermatologist if:
You are pregnant or plan to become pregnant. It is not known if SOTYKTU can
harm your unborn baby.
You are breastfeeding or plan to breastfeed. It is not known if SOTYKTU passes
into your breast milk.
Tell your dermatologist if you become pregnant or think you are pregnant during treatment
with SOTYKTU. Report pregnancies to Bristol-Myers Squibb by calling 1-800-721-5072.
Talk to your dermatologist about all of the medications you are taking, including:
  • Prescription medicines
  • Over-the-counter medicines
  • Vitamins
  • Herbal supplements
Keep a list of them to show your dermatologist and pharmacist when you get a new medicine.
What are the possible side effects of SOTYKTU?
SOTYKTU may cause serious side effects, including:
  • Changes in certain laboratory test results. Changes in laboratory tests have happened in some people taking SOTYKTU. Your dermatologist may do blood tests before you start taking SOTYKTU and during treatment with SOTYKTU to check for the following:
    • Increased triglycerides. Too much fat in your blood can cause problems with your heart.
    • Increased liver enzymes. If your liver enzymes increase too much, your dermatologist may need to do additional tests on your liver and may tell you to stop taking SOTYKTU if they think that SOTYKTU is harming your liver.
  • Potential risks from Janus kinase (JAK) inhibition. SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor. TYK2 is in the JAK family. It is not known whether taking SOTYKTU has the same risks as taking JAK inhibitors. Increased risk of death (all causes) has happened in people who were 50 years of age and older with at least 1 heart disease (cardiovascular) risk factor who were taking a JAK inhibitor used to treat rheumatoid arthritis (RA) compared to people taking another medicine in a class of medicines called TNF blockers. SOTYKTU is not for use in people with RA.
What are the most common side effects of SOTYKTU?
The most common side effects of SOTYKTU include:
  • Common cold, sore throat, and sinus infection (upper respiratory infections)
  • Cold sores (herpes simplex)
  • Sores on the inner lips, gums, tongue, or roof of the mouth (canker sores)
  • Inflamed hair pores (folliculitis)
  • Acne
These are not all of the possible side effects of SOTYKTU.
Talk to your dermatologist, pharmacist, or other members of your healthcare team for more information about side effects. If you experience any side effects and would like to report them to the FDA, you can visit www.fda.gov/medwatch or call 1-800-FDA-1088.
How should I take SOTYKTU?
Take SOTYKTU exactly as your
dermatologist tells you.
Take 1 time every day
Can be taken with or without food
Do not crush, cut, or chew the SOTYKTU tablets
SOTYKTU is available as a 6 milligram (mg) pink, round pill.
Each pill is marked with “BMS 895” and “6 mg.”
Do not take SOTYKTU if you are allergic to deucravacitinib or any of the ingredients in SOTYKTU.
Inactive ingredients: anhydrous lactose, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicon dioxide
Pill coating inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red and yellow
How should I store SOTYKTU?
Store SOTYKTU at room temperature between 68°F to 77°F (20°C to 25°C).
Keep SOTYKTU and all medicines out of reach of children.
For more information, please see the U.S. Full Prescribing Information and Medication Guide for SOTYKTU.
Talk to your healthcare team for more information about this medication.
1787-US-2300695 12/231787-US-2200851 02/23
1787-US-2200571 09/22
SOTYKTU and SOTYKTU logo are trademarks of
Bristol-Myers Squibb Company.
All other trademarks are property of their respective owners.
© 2023 Bristol-Myers Squibb Company.
1787-US-2200141 09/22
Legal Notice|Privacy Policy|
Your Privacy Choices |Site Map
This website is intended for U.S. residents
18 years of age or older.
SOTYKTU and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
Otezla is a registered trademark of Amgen Inc.
© 2024 Bristol-Myers Squibb Company.
1787-US-2400084 03/24
Legal Notice|Privacy Policy|
Your Privacy Choices |Site Map
This website is intended for U.S. residents
18 years of age or older.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.